Drug
LGH-447 clinical trials
Also written LGH447.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses LGH-447 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With MyelofibrosisCompletedPhase 1Novartis PharmaceuticalsNCT02370706Written as PIM447
- A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedPhase 1Novartis PharmaceuticalsNCT02078609Written as LGH447
- Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic MalignanciesCompletedPhase 1Novartis PharmaceuticalsNCT02160951Written as LGH447
Given in every arm · 2 — LGH-447 is usual care beside what is tested
- A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedPhase 1Novartis PharmaceuticalsNCT01456689Written as LGH447
- Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple MyelomaCompletedPhase 1Novartis PharmaceuticalsNCT02144038Written as LGH447
Codes
What other systems call LGH-447 · ClinicalTrials.gg INT001706
- MeSH (NLM) C000719080LGH-447One source NLM
- UNII (FDA) 9TG5O4V25HLGH-447Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719080 | LGH-447 | One source NLM |
| UNII (FDA) | 9TG5O4V25H | LGH-447 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.